Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

Primary Care, Blood-Based Biomarkers Key To Growth

 
• By Mandy Jackson
  
Primary care physician outreach is the next frontier in Eisai's Leqembi launch (Shutterstock)

More from Earnings

More from Scrip